Roswell Park Team Identifies New Cause of Chemotherapy Resistance in Triple-Negative Breast Cancer
On Jan. 10, 2025, researchers at Roswell Park Comprehensive Cancer Center have identified a previously unknown cause of…
Biotechnology | Disease | FDA | Life Science News | Oncology | Radiology | Therapeutics
FDA approved AstraZeneca’s Imfinzi for limited-stage small cell lung cancer
On Dec. 4, 2024, The U.S. Food and Drug Administration (FDA) announced approved of AstraZeneca’s blockbuster drug Imfinzi…
Biotechnology | Diagnostics | Disease | Genomics | Life Science News | Neurology | Oncology | Radiology | Therapeutics
Study revealed how deadly brain tumor evades treatment; identifies potential new treatment strategy
On Nov. 21, 2024, a study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why…
Combination approach showed promise for treating rare, aggressive cancers
On Nov. 12, 2024, a research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that…
Combination Chemo Helps People with Leiomyosarcoma Live Longer
On Oct. 2, 2024, results from a French clinical trial have identified what experts say should now be…
FDA Approved ‘First Gene Therapy’ to Treat Adults with Metastatic Synovial Sarcoma
On Aug. 2, 2024, the U.S. Food and Drug Administration approved Adaptimmune’s Tecelra (afamitresgene autoleucel), a gene therapy…
Biotechnology | Diagnostics | Life Science News | Non-Profit Research | Oncology | Radiology | Therapeutics
Fred Hutch to lead new federal Cancer Screening Research Network
On Feb. 21, 2024, the Fred Hutchinson Cancer Center announced it was at the helm of a new…
U.S. FDA approves cell therapy for patients with blood cancers to reduce risk of infection after stem cell transplantation
On Apr. 17, 2023, the U.S. FDA approved Gamida Cell’s Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord…
Biotechnology | Diagnostics | Life Science News | Non-Profit Research | Oncology | Radiology | Therapeutics
Hutchinson Cancer Center announced new “patient-centric” building in South Lake Union
On Mar. 23, 2023, the Fred Hutchinson Cancer Center (FHCRC) announced a new building in South Lake Union…
Biotechnology | Diagnostics | Disease | Life Science News | Oncology | Radiology | Therapeutics | Women's Health
Major study linked breast cancer treatment with increased risk of cardiovascular disease
On Apr. 6, 2022, a new study in the Journal of Clinical Oncology showed that women receiving certain…
Biotechnology | Diagnostics | Disease | FDA | Life Science News | Oncology | Radiology | Therapeutics
FDA approved Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
On Oct. 15, 2021, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Tecentriq (atezolizumab)…
Biotechnology | Diagnostics | Disease | FDA | Life Science News | Oncology | Radiology | Therapeutics
FDA approved LUMAKRAS for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
On May 28, 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved LUMAKRAS (sotorasib)…
Biotechnology | Diagnostics | Disease | FDA | Life Science News | Oncology | Radiology | Therapeutics
FDA approved first targeted therapy for subset of non-small cell lung cancer
On May 21, 2021, the the U.S. Food and Drug Administration (FDA) approved Rybrevant (amivantamab-vmjw) as the first…
FDA approved first immunotherapy for initial treatment of gastric cancer
On Apr. 16, 2021, the FDA approved Bristol-Myers Squibb’ s Opdivo (nivolumab), in combination with certain types of…
Dr. James Lim and Lakshana Sreenivasan discovered that certain immune signals may help medulloblastoma resist chemotherapy
On Dec. 5, 2020, Dr. James Lim and Lakshana Sreenivasan discovered that certain immune signals may help medulloblastoma…
Agilent received expanded FDA approval for PD-L1 IHC 22C3 pharmDx in triple-negative breast cancer
On Nov. 13, 2020, Agilent Technologies announced it had received U.S. Food and Drug Administration (FDA) approval for…
FDA approved Merck’s KEYTRUDA (pembrolizumab) in combination with chemo for patients with TNBC
On Nov. 13, 2020, Merck announced that the U.S. Food and Drug Administration (FDA) had approved KEYTRUDA, Merck’s…
FDA approved Bristol-Myers’ Opdivo’ (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinoma
On Jun. 11, 2020, Bristol-Myers Squibb announced that Opdivo (nivolumab) was approved by the FDA for the treatment…
Study confirmed effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
On May 26, 2020, the NIH announced a new study that provides an alternative treatment regimen that is…
Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
On Apr. 27, 2020, Regeneron and Sanofi announced the primary endpoint of overall survival was met in a…
Biotechnology | Disease | FDA | Life Science News | Oncology | Therapeutics
FDA approved first new drug under international collaboration for patients with HER2-positive metastatic breast cancer
On Apr. 17, 2020, as part of Project Orbis, the U.S. Food and Drug Administration (FDA) approved Seagen’s…
FDA granted accelerated approval to Astellas and Seagen PADCEV for people with locally advanced or metastatic urothelial cancer
On Dec. 18, 2019, Seagen and Astellas Pharma announced the U.S. Food and Drug Administration (FDA) had granted…
St. Jude announced a cure for SCID-X1, commonly known as bubble boy disease
On Apr. 18, 2019, St. Jude announced a cure for SCID-X1, commonly known as bubble boy disease. By…
FDA approved gilteritinib, a targeted drug for leukemia tested at UPenn
On Nov. 28, 2018, The U.S. Food and Drug Administration (FDA) announced it had approved the first ever…
TAILOR trial found most women with early breast cancer do not benefit from chemotherapy
On Jun. 3, 2018, findings were reported from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or…
Biotechnology | Chemical | Disease | FDA | Life Science News | Oncology | Therapeutics
Genentech drug Tecentriq (atezolizumab) was approved
On Oct. 18, 2016, the U.S. Food and Drug Administration (FDA) approved TECENTRIQ® (atezolizumab) for the treatment of…
FDA approved Genentech’s Avastin plus chemotherapy for treatment of advanced cervical cancer
On Aug. 14. 2014, Genentech announced that the U.S. Food and Drug Administration (FDA) had approved Avastin (bevacizumab)…
Biotechnology | CDC | Influenza | Life Science News | Non-Profit Research | Radiology | Stem Cell | Vaccine
CDC published ACIP recommendations for prevention and control ofï¾ Haemophilus influenzaeï¾ type b (Hib) ï¾ disease
On Feb. 28, 2014, the U.S. Centers for Disease Control and Prevention (CDC) published Immunization Practices Advisory Committee…
Genentech drug Perjeta (pertuzumab) was approved
On Jun. 8, 2012, the U.S. Food and Drug Administration (FDA) announced that Genentech’s drug Perjeta (pertuzumab) was…
Biotechnology | Diagnostics | Disease | Life Science News | Non-Profit Research | Oncology | Radiology | Therapeutics
Duke Cancer Institute opened the Duke Cancer Center, a new 7-floor building
On Feb. 27, 2012, the Duke Cancer Institute opened a new 267,000-square-foot, $235 million Cancer Center that included…